ENDOSTATIN:a possible revival? Also preview of a few Apr 07 AACR presentations

[heblaj01]

Back in 1998 & in the next few years Endostatin (alone or in combination with Angiostatin) demonstrated tremendous results as an antiangiogenesis drug in mice experiments. Human trials were not as successful & stopped at the phase 2 stage due to both technical & funding problems. The synthesized version of the endogenous molecule was very expensive to produce, required refrigeration & as a large molecule was not well absorbed & with a short life in the body which would have required continuous infusion for optimum results.

The following abstract of a presentation to be made in mid April at the American Association of Clinical for Cancer Research (AACR) describes a derivative version of Endostatin which overcomes some of its drawbacks & opens up new trial possibilities.

An earlier attempt to inprove the drug, (by fusing Endostatin to an antibody specific for the tumor-selective ^{HER-2 antigen is linked below.}
Actually, Endostatin, discovered at harvard, did not completely fade away after its first false start. A Chinese researcher of the Harvard lab of Dr Folkman developed a derivative called Endostar which is approved in China.
Among the 6000 or so presentations planed for the 2007 AACR meeting I happened to accidentally find a few which relate to subjects dealt in the past in this Forum.

http://www.abstractsonline.com/viewe...C-7EAE187DB124}

<sup>4598--Tuesday, 1:00 p.m. - 5:00 p.m.--Improved pharmacokinetics and efficacy of endostatin by fusion with IgG Fc domain



http://webreprints.djreprints.com/1377770914678.html

Second Chance
Once-Touted Drug For Cancer Finds New Life in China

================================================== =========

http://mct.aacrjournals.org/cgi/content/full/4/6/956

Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein

================================================== =============================

Selected AACR presentation & lectures:

aacr Tuesday, April 17, 2007
Progress in Metronomic Antiangiogenic Chemotherapy
Robert S. Kerbel, Sunnybrook Health Sciences Center, Toronto, Ontario,Canada

Centennial Lecture
Targeting PI3K in Cancer
Lewis C. Cantley, Beth Israel Deaconess Medical Center, Boston, MA

Centennial Lecture
What Is the Potential Future for Angiogenesis-based Biomarkers?
Judah Folkman, Harvard Medical School, Boston, MA
http://www.abstractsonline.com/viewe...C-7EAE187DB124}
4611--Tuesday, 1:00 p.m. - 5:00 p.m.--Sulforaphane induces apoptosis of endothelial progenitor cells
http://www.abstractsonline.com/viewe...C-7EAE187DB124}
4625--Tuesday, 1:00 p.m. - 5:00 p.m.--In vivo function of vitamin D receptor (VDR) in tumor angiogenesis
http://www.abstractsonline.com/viewe...F-D4C3675E5AE2}

Zoledronic acid inhibits the earliest stages of vasculogenesis: blockage of the transdifferentiation of monocytes into endothelial cells induced by pleiotrophin and mCSF

http://www.abstractsonline.com/viewe...F-D4C3675E5AE2}
Anti-angiogenic activity of Zoledronic acid by inhibition of endothelial progenitor cells differentiation</sup>